EUVIMEDEUVIMED entdecken
Crossref

Approach to the Patient: Central Precocious Puberty

Marissa J Kilberg, Maria G Vogiatzi iD

The Journal of Clinical Endocrinology & Metabolism · 14.07.2023 · 108 (8) · 2115-2123

DOI: 10.1210/clinem/dgad081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.03.2023. Verfasst von Marissa J Kilberg und 1 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, Endocrinology and Diabetes, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Puberty, Precocious. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central precocious puberty (CPP) classically refers to premature activation of the hypothalamic–pituitary–gonadal axis with onset of sexual development before the age of 8 years in girls and 9 years in boys. A decrease in the age of thelarche has been reported over the past several decades; however, the tempo of pubertal progression can be slower and adult height may not be adversely affected in many of the girls who experience thelarche at 6-8 years. Outside of this secular trend in the development itself, the past several decades have also brought about advances in diagnosis and management. This includes the widespread use of an ultrasensitive luteinizing hormone assay, decreasing the need for stimulation testing and a better understanding of the genetics that govern the onset of puberty. Additionally, management of CPP using gonadotropin-releasing hormone analogs (GnRHas) has changed with the advent of new longer-acting formulations. Emerging long-term outcomes of GnRHa administration with regards to obesity, cardiovascular risk factors and fertility are reassuring. Despite these advancements, clinical care in CPP is hampered by the lack of well-designed controlled studies, and management decisions are frequently not supported by clear practice guidelines. Data in boys with CPP are limited and this article focuses on the diagnosis and management of CPP in girls, particularly, in those who present with thelarche at the age of 6-8 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gonadotropin-Releasing HormonePuberty, PrecociousFemaleMaleHumansChildSexual DevelopmentFertilityHeart Disease Risk FactorsFollicle Stimulating Hormone

Stichwörter der Autor:innen

GnRH analogsprecocious pubertythelarche

Substanzen

Gonadotropin-Releasing HormoneFollicle Stimulating Hormone

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia, Endocrinology and Diabetes, Philadelphia, PA 19104, USA.

ORCID-Profile: Maria G Vogiatzi

Zitieren

APA

Kilberg, M. J., & Vogiatzi, M. G. (2023). Approach to the Patient: Central Precocious Puberty. The Journal of Clinical Endocrinology & Metabolism, 108(8), 2115-2123. https://doi.org/10.1210/clinem/dgad081

Vancouver

Kilberg MJ, Vogiatzi MG. Approach to the Patient: Central Precocious Puberty. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):2115-2123. doi:10.1210/clinem/dgad081

BibTeX
@article{Kilberg2023,
  author = {Kilberg, Marissa J and Vogiatzi, Maria G},
  title = {Approach to the Patient: Central Precocious Puberty},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {8},
  pages = {2115--2123},
  doi = {10.1210/clinem/dgad081}
}
Kostenlos starten →